Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enanta Pharmaceuticals Inc.

www.enanta.com

Latest From Enanta Pharmaceuticals Inc.

Enanta Stumbles In Trying To Show Better FXR Agonist Profile In NASH

Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.

Clinical Trials Commercial

Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach

Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.

Clinical Trials Respiratory

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.

Clinical Trials Liver & Hepatic

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.

Deals Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Enanta Pharmaceuticals Inc.
  • Senior Management
  • Jay R Luly, PhD, Pres. & CEO
    Paul J Mellett, SVP, Fin. & Admin. & CFO
    Yat Sun Or, PhD, SVP, R&D & CSO
  • Contact Info
  • Enanta Pharmaceuticals Inc.
    Phone: (617) 607-0800
    500 Arsenal St.
    Watertown, MA 02472
    USA
UsernamePublicRestriction

Register